PL4459282T3 - Przeciwciało monoklonalne przeciwko IL-31 - Google Patents

Przeciwciało monoklonalne przeciwko IL-31

Info

Publication number
PL4459282T3
PL4459282T3 PL24200176.6T PL24200176T PL4459282T3 PL 4459282 T3 PL4459282 T3 PL 4459282T3 PL 24200176 T PL24200176 T PL 24200176T PL 4459282 T3 PL4459282 T3 PL 4459282T3
Authority
PL
Poland
Prior art keywords
monoclonal antibody
antibody against
monoclonal
antibody
Prior art date
Application number
PL24200176.6T
Other languages
English (en)
Inventor
Gary F. BAMMERT
Steven A. DUNHAM
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46704979&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL4459282(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of PL4459282T3 publication Critical patent/PL4459282T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL24200176.6T 2011-07-21 2012-07-05 Przeciwciało monoklonalne przeciwko IL-31 PL4459282T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161510268P 2011-07-21 2011-07-21

Publications (1)

Publication Number Publication Date
PL4459282T3 true PL4459282T3 (pl) 2026-01-26

Family

ID=46704979

Family Applications (5)

Application Number Title Priority Date Filing Date
PL12748547T PL2734549T3 (pl) 2011-07-21 2012-07-05 Przeciwciało monoklonalne przeciwko psiej interleukinie 31
PL17168574T PL3219729T3 (pl) 2011-07-21 2012-07-05 Przeciwciało monoklonalne przeciwko IL-31
PL19196963.3T PL3653645T3 (pl) 2011-07-21 2012-07-05 Przeciwciało monoklonalne przeciwko IL-31
PL24200176.6T PL4459282T3 (pl) 2011-07-21 2012-07-05 Przeciwciało monoklonalne przeciwko IL-31
PL20194926.0T PL3842456T3 (pl) 2011-07-21 2012-07-05 Przeciwciało monoklonalne przeciwko IL-31

Family Applications Before (3)

Application Number Title Priority Date Filing Date
PL12748547T PL2734549T3 (pl) 2011-07-21 2012-07-05 Przeciwciało monoklonalne przeciwko psiej interleukinie 31
PL17168574T PL3219729T3 (pl) 2011-07-21 2012-07-05 Przeciwciało monoklonalne przeciwko IL-31
PL19196963.3T PL3653645T3 (pl) 2011-07-21 2012-07-05 Przeciwciało monoklonalne przeciwko IL-31

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL20194926.0T PL3842456T3 (pl) 2011-07-21 2012-07-05 Przeciwciało monoklonalne przeciwko IL-31

Country Status (25)

Country Link
US (7) US8790651B2 (pl)
EP (6) EP3219729B1 (pl)
JP (1) JP6022563B2 (pl)
KR (2) KR101613024B1 (pl)
CN (2) CN105504059B (pl)
AR (1) AR087281A1 (pl)
AU (2) AU2012285432C1 (pl)
BR (1) BR112014001407A8 (pl)
CA (2) CA2926379A1 (pl)
CY (2) CY1119475T1 (pl)
DK (4) DK3842456T3 (pl)
ES (4) ES2827231T3 (pl)
FI (3) FI4459282T3 (pl)
HR (5) HRP20251544T1 (pl)
HU (4) HUE068973T2 (pl)
LT (5) LT2734549T (pl)
ME (1) ME02837B (pl)
MX (2) MX349053B (pl)
PL (5) PL2734549T3 (pl)
PT (5) PT3219729T (pl)
RS (5) RS56268B1 (pl)
SI (5) SI4459282T1 (pl)
UY (1) UY34206A (pl)
WO (1) WO2013011407A1 (pl)
ZA (1) ZA201400768B (pl)

Families Citing this family (172)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0316282B8 (pt) * 2002-11-15 2021-05-25 Genmab As anticorpo humano isolado monoclonal, composição, imunoconjugado, molécula biespecífica ou multiespecífica, método e conjunto de diagnóstico para detectar a presença de antígeno cd25 ou uma célula que expressa cd25, e, vetor de expressão
EP3345607B1 (en) 2006-12-29 2022-10-26 Ossifi-Mab LLC Methods of altering bone growth by administration of sost or wise antagonist or agonist
WO2008100624A2 (en) * 2007-02-16 2008-08-21 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof
EP2215120A2 (en) 2007-12-07 2010-08-11 ZymoGenetics, Inc. Humanized antibody molecules specific for il-31
SMT202000095T1 (it) * 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
DK2582391T3 (en) 2010-06-18 2019-01-21 Xbiotech Inc ARTHRITIS TREATMENT
MX349057B (es) * 2010-11-30 2017-07-07 Chugai Pharmaceutical Co Ltd Agente terapeutico que induce citotoxicidad.
EP4086338A1 (en) 2011-03-17 2022-11-09 Minerva Biotechnologies Corporation Method for making pluripotent stem cells
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
HK1211958A1 (en) * 2012-08-21 2016-06-03 Ortho-Clinical Diagnostics, Inc. Antibodies to paliperidone and use thereof
CN107043424B (zh) 2012-08-21 2021-03-16 詹森药业有限公司 利培酮的抗体及其用途
AU2013322628B2 (en) * 2012-09-26 2017-03-02 Julius-Maximilians-Universitat Wurzburg Monoclonal antibodies to growth and differentiation factor 15 (GDF-15)
AU2013364133B2 (en) * 2012-12-21 2018-10-11 Aveo Pharmaceuticals, Inc. Anti-GDF15 antibodies
AU2013364043B2 (en) * 2012-12-21 2018-01-04 Seagen Inc. Anti-NTB-A antibodies and related compositions and methods
WO2014168933A1 (en) * 2013-04-08 2014-10-16 Cytodyn Inc. Felinized antibodies and methods of treating retroviral infections in felines
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
CN113150164A (zh) * 2013-07-25 2021-07-23 西托姆克斯治疗公司 多特异性抗体、多特异性可活化抗体及其使用方法
JP6556742B2 (ja) * 2013-11-06 2019-08-07 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｃｌ１７抗体
US11072647B2 (en) * 2013-12-19 2021-07-27 Onsejo Nacional DE Investigation Cientiticay Tecnica TGF-receptor II isoform, fusion peptide, methods of treatment and methods in vitro
PT3083694T (pt) * 2013-12-20 2024-02-01 Intervet Int Bv Anticorpos murinos caninizados anti-pd-1 canino
ES2923641T3 (es) * 2013-12-30 2022-09-29 Epimab Biotherapeutics Inc Inmunoglobulina con Fabs en tándem y usos de la misma
US11485787B2 (en) * 2014-02-05 2022-11-01 Dana-Farber Cancer Institute, Inc. Agents that modulate RGMb-neogenin-BMP signaling and methods of use thereof
CN113388032A (zh) * 2014-02-06 2021-09-14 X4制药(奥地利)有限责任公司 大肠杆菌特异性抗体序列
HUE047398T2 (hu) * 2014-03-26 2020-04-28 Univ Wuerzburg J Maximilians Növekedési és differenciálódási faktor 15 (GDF-15) elleni monoklonális antitestek és azok alkalmazásai rákos sorvadás és rák kezelésére
JP6910800B2 (ja) * 2014-06-20 2021-07-28 アベオ ファーマシューティカルズ， インコーポレイテッド Ｇｄｆ１５調節剤を用いたうっ血性心不全及びその他の心機能不全の治療
US9212225B1 (en) * 2014-07-01 2015-12-15 Amphivena Therapeutics, Inc. Bispecific CD33 and CD3 binding proteins
ES2833425T3 (es) * 2014-07-16 2021-06-15 Roussy Inst Gustave Combinación de virus oncolítico con moduladores de punto de control inmunitario
HUE054670T2 (hu) * 2014-09-25 2021-09-28 Aveo Pharmaceuticals Inc Módszer cachexia visszafordítására és túlélés megnövelésére egy GDF15 modulátor és egy rákellenes szer adagolásával
MA40824A (fr) * 2014-10-22 2017-08-29 Saiba Gmbh Particules de cmv de type virus modifié
WO2016075612A1 (en) * 2014-11-12 2016-05-19 Rinat Neuroscience Corp. Inhibitory chimeric antigen receptors
US10849862B2 (en) * 2014-12-26 2020-12-01 Theravalues Corporation Formulation of curcumin and anti-PD-1 antibody
TWI703156B (zh) * 2015-01-30 2020-09-01 學校法人埼玉醫科大學 抗ａｌｋ２抗體
TW201632559A (zh) * 2015-02-22 2016-09-16 索倫多醫療公司 結合ｃｄ１３７之抗體治療劑
CA2982400C (en) * 2015-03-31 2023-10-24 Medimmune Limited A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same
KR102514173B1 (ko) 2015-04-14 2023-03-27 추가이 세이야쿠 가부시키가이샤 Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물
US11424061B2 (en) * 2015-04-14 2022-08-23 Hanchett Entry Systems, Inc. Solenoid assembly actuation using resonant frequency current controller circuit
US12567526B2 (en) 2015-04-14 2026-03-03 Hanchett Entry Systems, Inc. Solenoid assembly with included constant-current controller circuit
JP2018516248A (ja) 2015-05-29 2018-06-21 アンフィヴェナ セラピューティクス，インク． 二重特異性のｃｄ３３およびｃｄ３結合タンパク質を使用する方法
CN106336459B (zh) * 2015-07-13 2020-12-08 三生国健药业（上海）股份有限公司 抗人白细胞介素-17a单克隆抗体、其制备方法和应用
ES2968226T3 (es) 2015-10-02 2024-05-08 Univ Wuerzburg J Maximilians GDF-15 como marcador de diagnóstico para predecir la evolución clínica de un tratamiento con bloqueadores de puntos de control inmunitario
TWI752920B (zh) 2015-10-12 2022-01-21 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
US10815304B2 (en) * 2015-11-17 2020-10-27 Suzhou Suncadia Biopharmaceuticals Co., Ltd. PD-L1 antibody, antigen-binding fragment thereof and medical application thereof
JP6949025B2 (ja) 2015-12-17 2021-10-13 ヤンセン ファーマシューティカ エヌ．ベー． リスペリドンに対する抗体及びその使用
WO2017123745A1 (en) * 2016-01-12 2017-07-20 Palleon Pharma Inc. Use of siglec-7 or siglec-9 antibodies for the treatment of cancer
MX394254B (es) * 2016-04-27 2025-03-24 Benchmark Animal Health Ltd Composiciones para el tratamiento de dermatitis atópica canina y sus usos.
CN113372446A (zh) * 2016-06-08 2021-09-10 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
CA3027651A1 (en) * 2016-06-15 2017-12-21 Novartis Ag Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6)
CN117683135A (zh) 2016-07-14 2024-03-12 百时美施贵宝公司 针对tim3的抗体及其用途
HUE067888T2 (hu) 2016-09-01 2024-11-28 Regeneron Pharma Módszerek az allergia megelõzésére vagy kezelésére egy IL-4R antagonista adagolásával
WO2018057735A1 (en) * 2016-09-21 2018-03-29 Nextcure, Inc. Antibodies for siglec-15 and methods of use thereof
CN118359705A (zh) * 2016-10-19 2024-07-19 英温拉公司 抗体构建体
WO2018089532A1 (en) 2016-11-08 2018-05-17 Regeneron Pharmaceuticals, Inc. Antigen-binding proteins that antagonize leptin receptor
JP7127859B2 (ja) 2016-11-09 2022-08-30 ノース カロライナ ステート ユニバーシティ キメラタンパク質を用いたアレルギー疾患の治療
CN117442720A (zh) * 2016-12-21 2024-01-26 美莱奥生物制药第三有限公司 抗硬化蛋白抗体在治疗成骨不全症中的用途
EP3574017A1 (en) 2017-01-27 2019-12-04 Kymab Limited Anti-opg antibodies
CA3053231A1 (en) * 2017-02-16 2018-08-23 Xbiotech Inc. Treatment of hidradenitis suppurativa
EP3585430A4 (en) 2017-02-21 2020-12-09 REMD Biotherapeutics, Inc. TREATMENT OF CANCER WITH ANTIBODIES THAT BIND TO T-CYTOTOXIC T-LYMPHOCYTES ANTIGEN-4 (CTLA-4)
WO2018156367A1 (en) * 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
AU2018246377B2 (en) 2017-03-31 2025-01-30 Cellectis Sa Universal anti-CD22 chimeric antigen receptor engineered immune cells
MX2019012233A (es) * 2017-04-13 2020-01-14 Aduro Biotech Holdings Europe Bv Anticuerpos anti-sirpa.
AU2018273174B2 (en) * 2017-05-26 2021-10-14 Glaxosmithkline Intellectual Property Development Limited Biopharmaceutical compositions and related methods
KR20200012920A (ko) * 2017-06-01 2020-02-05 지앙수 헨그루이 메디슨 컴퍼니 리미티드 항-cd40 항체, 이의 항원 결합 단편 및 이의 의학적 용도
US20210405044A1 (en) * 2017-06-28 2021-12-30 Becton, Dickinson And Company Sandwich-type assays using decreasing signal portions of dose response curve to measure analytes, including analytes at high concentration
TWI726228B (zh) * 2017-08-09 2021-05-01 國立臺灣大學 Ｃｄ１４拮抗分子用於治療癌症
KR20200037388A (ko) * 2017-08-16 2020-04-08 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16, 및 egfr, hla-e, ccr4 또는 pd-l1에 결합하는 단백질
JP7226833B2 (ja) * 2017-09-21 2023-02-21 イムチェック セラピューティクス エスエーエス Ｂｔｎ２に特異性を有する抗体及びその使用
RU2698048C2 (ru) * 2017-10-03 2019-08-21 Закрытое Акционерное Общество "Биокад" МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
IL321773A (en) 2017-10-14 2025-08-01 Cytomx Therapeutics Inc Activatable antibodies and methods for preparing them
WO2019086694A1 (en) 2017-11-06 2019-05-09 Geert Mudde Il31 antigen and vaccine
US12534517B2 (en) * 2017-11-21 2026-01-27 The University Of Vermont And State Agricultural College Highly specific zika neutralizing human antibodies
MX2020006105A (es) * 2017-12-11 2020-11-09 Ubi Ip Holdings Inmunógenos peptídicos de il-31 y formulaciones de estos para el tratamiento y/o la prevención de la dermatitis atópica.
KR20200100089A (ko) 2017-12-18 2020-08-25 리제너론 파마슈티칼스 인코포레이티드 렙틴 수용체 및/또는 gp130에 결합하는 이중 특이적 항원 결합 분자 및 이의 사용 방법
CN109957026A (zh) * 2017-12-22 2019-07-02 成都恩沐生物科技有限公司 共价多特异性抗体
KR102813913B1 (ko) 2018-01-12 2025-05-30 브리스톨-마이어스 스큅 컴퍼니 Tim3에 대한 항체 및 그의 용도
WO2019151418A1 (ja) * 2018-01-31 2019-08-08 元一 加藤 Ｉｌ－６阻害剤を含有する喘息の治療剤
JP2021512914A (ja) 2018-02-08 2021-05-20 ドラゴンフライ セラピューティクス， インコーポレイテッド ナチュラルキラー細胞を活性化する多特異的結合タンパク質を伴うがんの併用療法
CN120137046A (zh) 2018-02-08 2025-06-13 蜻蜓疗法股份有限公司 靶向nkg2d受体的抗体可变结构域
MX2020008193A (es) * 2018-02-09 2020-11-24 Nestle Skin Health Sa Nemolizumab en el tratamiento de dermatitis atópica con excoriación moderada a severa.
KR102832460B1 (ko) 2018-02-20 2025-07-11 드래곤플라이 쎄라퓨틱스, 인크. Cd33, nkg2d, 및 cd16에 결합하는 다중-특이적 결합 단백질, 및 이의 사용 방법
CA3093539A1 (en) 2018-03-16 2019-09-19 Zoetis Services Llc Interleukin-31 monoclonal antibodies for veterinary use
BR112020017715A2 (pt) 2018-03-16 2020-12-29 Zoetis Services Llc Vacinas de peptídeo contra interleucina-31
WO2019177138A1 (ja) * 2018-03-16 2019-09-19 国立大学法人滋賀医科大学 異常ｔｄｐ－４３を分解除去する抗体断片
WO2019183437A1 (en) 2018-03-23 2019-09-26 North Carolina State University Methods and compositions for antibody to high affinity receptor for ige
AU2019249273B2 (en) * 2018-04-06 2026-02-05 Regeneron Pharmaceuticals, Inc. Methods of treatment using a leptin receptor agonist antibody
CN112105629B (zh) * 2018-05-09 2025-09-12 古德T细胞有限公司 调节性t细胞表面抗原的表位以及与其特异性结合的抗体
EP3806885A2 (en) * 2018-06-13 2021-04-21 Kymab Limited Antagonists and agonists of the transferrin receptor-2 for use in the treatment of diseases of the bone
TWI822815B (zh) * 2018-07-14 2023-11-21 財團法人生物技術開發中心 抗-人類ｐｄ-ｌ１之抗體及其用途
SG11202101152QA (en) 2018-08-03 2021-03-30 Chugai Pharmaceutical Co Ltd Antigen-binding molecule containing two antigen-binding domains that are linked to each other
US12161890B2 (en) * 2018-08-07 2024-12-10 Cz Biohub Sf, Llc Antibodies against dengue virus and related methods
EP3833385A4 (en) 2018-08-08 2021-12-22 Dragonfly Therapeutics, Inc. PROTEINS THAT BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN
AR114544A1 (es) 2018-08-08 2020-09-16 Dragonfly Therapeutics Inc Proteínas de unión multiespecíficas que unen a bcma, nkg2d y cd16, y métodos de uso
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
BR112021003173A2 (pt) * 2018-08-20 2021-05-11 Pfizer Inc. anticorpos anti-gdf15, composições e métodos de uso
CN113166247A (zh) * 2018-09-28 2021-07-23 中外制药株式会社 能够结合cd3和cd137但不同时结合cd3和cd137的抗原结合分子
WO2020077120A1 (en) * 2018-10-10 2020-04-16 The Board Of Trustees Of The Leland Stanford Junior University BLOCKADE OF RGMb FOR TREATING INFLAMMATORY BOWEL DISEASE AND COLITIS
TW202039587A (zh) * 2018-12-19 2020-11-01 美商聯合生物醫學公司 供合成胜肽免疫原作為免疫刺激劑的人工混雜t輔助細胞抗原決定位
EP3898673A1 (en) * 2018-12-21 2021-10-27 23Andme, Inc. Anti-il-36 antibodies and methods of use thereof
US20220082573A1 (en) * 2018-12-29 2022-03-17 Berysol Gmbh Selenium binding protein 1 detection from body fluids for diagnosis of peracute tissue damage
CN120005022A (zh) 2019-01-03 2025-05-16 因外泰克斯公司 用于增加治疗剂在犬中的半衰期的组合物及使用方法
CA3132587A1 (en) * 2019-03-21 2020-09-24 Regeneron Pharmaceuticals, Inc. Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
AU2020248645A1 (en) * 2019-03-27 2021-10-28 Tigatx, Inc. Engineered IgA antibodies and methods of use
KR20220050087A (ko) * 2019-05-03 2022-04-22 싱가포르 헬스 서비시즈 피티이 엘티디 대사성 질환의 치료 및 예방
CN110283246A (zh) * 2019-06-20 2019-09-27 长春西诺生物科技有限公司 一种抗猫细小病毒的猫源化基因工程抗体
CN119307505A (zh) * 2019-07-15 2025-01-14 英特维特国际股份有限公司 针对人和犬ctla-4的犬源化抗体
BR112022000249A2 (pt) 2019-07-30 2022-05-17 Kindred Biosciences Inc Anticorpos de parvovírus para uso veterinário
CN120866510A (zh) * 2019-08-12 2025-10-31 雷杰纳荣制药公司 巨噬细胞刺激1受体(mst1r)变体及其用途
EP3820907A4 (en) * 2019-08-27 2022-05-04 Elpiscience (Suzhou) Biopharma, Ltd. NOVEL ANTI-CD39 ANTIBODIES
AU2020339478A1 (en) * 2019-08-29 2021-05-06 Remegen Co., Ltd. Anti PD-L1 antibody and use thereof
MX2022002360A (es) * 2019-08-29 2022-04-06 Kindred Biosciences Inc Anticuerpos de anti-il31 para uso veterinario.
WO2021048285A1 (en) * 2019-09-14 2021-03-18 Immundiagnostik Ag Medicinal preparation for treating fibrosis with anti bsp antibodies
CN115023440B (zh) 2019-09-23 2025-09-12 特韦斯特生物科学公司 结合CD3ε的抗体
CN112569358B (zh) * 2019-09-30 2022-06-28 上海生物制品研究所有限责任公司 培干扰素和原癌基因产物靶向抑制剂在协同抑制肿瘤中的应用
PH12022550740A1 (en) * 2019-09-30 2023-05-08 Janssen Pharmaceutica Nv Compositions and methods for an il-17 target engagement assay with small molecule modulators
US11890353B2 (en) * 2019-10-15 2024-02-06 Northwestern University Anti-polyethylene glycol (PEG) antibody mouse model for rigorous assessment of PEG-based therapies
CA3156713A1 (en) 2019-11-20 2021-05-27 Daisuke Kameoka Antibody-containing preparation
KR20220111308A (ko) * 2019-12-06 2022-08-09 소티오 바이오테크 에이.에스. 인간화 cldn18.2 항체
ES3033945T3 (en) * 2019-12-06 2025-08-11 Korea Atomic Energy Res Anti-tm4sf4 antibody and use thereof
BR112022011323A2 (pt) * 2019-12-10 2022-08-23 Abl Bio Inc Anticorpo biespecífico anti-antígeno de maturação de célula b (bcma)/anti-4-1bb ou um fragmento de ligação ao antígeno do mesmo, e composição farmacêutica para prevenção ou tratamento de uma doença relacionada ao bcma, 4-1bb ou ambos
US12545738B2 (en) 2019-12-20 2026-02-10 Intervet Inc. Canine interleukin-4 receptor alpha antibodies
CA3161496A1 (en) 2019-12-20 2021-06-24 Mohamad Morsey Bispecific caninized antibodies for treating atopic dermatitis
CN113134081A (zh) * 2020-01-20 2021-07-20 上海君实生物医药科技股份有限公司 抗btla抗体药物组合物及其用途
US20230340112A1 (en) * 2020-02-28 2023-10-26 Apexigen, Inc. Anti-sirpa antibodies and methods of use
US11987640B2 (en) * 2020-04-07 2024-05-21 Fred Hutchinson Cancer Center Anti-mesothelin antigen-binding molecules and uses thereof
US20230374114A1 (en) * 2020-04-16 2023-11-23 Dana-Farber Cancer Institute, Inc. Coronavirus antibodies and methods of use thereof
PH12022552743A1 (en) * 2020-04-17 2024-03-25 Zoetis Services Llc Feline antibody variants
PE20230108A1 (es) 2020-04-17 2023-01-25 Zoetis Services Llc Variantes de anticuerpos caninos
CN120535633A (zh) * 2020-04-24 2025-08-26 米伦纽姆医药公司 抗cd19抗体及其用途
US12157771B2 (en) 2020-05-06 2024-12-03 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and CLEC12A
WO2021223719A1 (zh) * 2020-05-08 2021-11-11 亘喜生物科技（上海）有限公司 一种抗cd19抗体的抗体及其制备和应用
AU2021270564A1 (en) 2020-05-11 2023-02-02 Invetx, Inc. Compositions for increasing half-life of a therapeutic agent in canines and methods of use
US20250154267A2 (en) * 2020-05-22 2025-05-15 Regeneron Pharmaceuticals, Inc. Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
CN119899259A (zh) 2020-07-10 2025-04-29 因外泰克斯公司 用于延长治疗剂在猫科动物中的半衰期的组合物和使用方法
MX2023001490A (es) 2020-08-05 2023-04-27 Synthekine Inc Moleculas de union a il27r\03b1 y metodos de uso.
WO2022032045A1 (en) 2020-08-05 2022-02-10 Synthekine, Inc. IL10Rα/IL2Rγ SYNTHETIC CYTOKINES
US12122839B2 (en) 2020-08-05 2024-10-22 Synthekine, Inc. IFNGR binding synthetic cytokines and methods of use
KR20230061391A (ko) 2020-08-05 2023-05-08 신테카인, 인크. gp130 결합 분자 및 사용 방법
JP7665730B2 (ja) * 2020-08-05 2025-04-21 シンセカイン インコーポレイテッド Ｉｌ２７受容体結合に関連する組成物および方法
WO2022031890A1 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Ifngr2 binding molecules and methods of use
AU2021321525A1 (en) 2020-08-05 2023-03-30 Synthekine, Inc. IL10 receptor binding molecules and methods of use
GB202012331D0 (en) 2020-08-07 2020-09-23 Petmedix Ltd Therapeutic antibodies
FR3113458B1 (fr) 2020-08-21 2022-10-14 Purally Composition comprenant au moins un flavonoide glycosyle et son utilisation en cosmetique ou dermatologie
AR123306A1 (es) * 2020-08-21 2022-11-16 Genzyme Corp Anticuerpos fgfr3 y métodos de uso
US20240010716A1 (en) 2020-09-28 2024-01-11 Zoetis Services Llc Canine antibody variants
PE20240110A1 (es) 2020-09-29 2024-01-22 Zoetis Services Llc Variantes de anticuerpos felinos
EP4229083A1 (en) 2020-10-15 2023-08-23 Intervet International B.V. Caninized antibodies to canine interleukin-31 receptor alpha
TWI904261B (zh) 2020-10-19 2025-11-11 美商碩騰服務公司 犬及貓抑瘤素Ｍ受體β之抗體及其用途
US11739137B2 (en) * 2020-10-30 2023-08-29 The Government Of The United States Of America, As Represented By The Secretary Of The Navy Single domain antibodies to SARS-CoV-2 nucleocapsid protein
US20220144956A1 (en) * 2020-11-06 2022-05-12 Xencor, Inc. HETERODIMERIC ANTIBODIES THAT BIND TGFbetaRII
AU2021376864A1 (en) 2020-11-10 2023-06-29 Catalym Gmbh Anti-gdf15 antibody and a dosage regimen for the treatment of cancer
AU2021383841A1 (en) * 2020-11-23 2023-06-22 Scout Bio, Inc. Antigen-binding molecules and uses thereof
IL303732A (en) * 2020-12-18 2023-08-01 Zoetis Services Llc Mutations in feline antibody constant regions
CA3207285A1 (en) 2021-01-28 2022-08-04 Zoetis Services Llc Mutations in canine antibody constant regions
EP4284830A1 (en) 2021-01-29 2023-12-06 Bayer Animal Health GmbH Vaccine composition for breaking self-tolerance
PE20240591A1 (es) * 2021-02-17 2024-03-21 Gammadelta Therapeutics Ltd Anticuerpos anti-variable delta 1 de tcr multiespecificos
BR112023016043A2 (pt) 2021-02-22 2023-12-05 Zoetis Services Llc Modelo de prurido induzido por il-31 de cavalo
US12377144B2 (en) 2021-03-03 2025-08-05 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen
JP2024511137A (ja) 2021-03-22 2024-03-12 ノビミューン エスアー Ｃｄ４７およびｐｄ－ｌ１を標的とする二重特異性抗体ならびにその使用方法
CA3212599A1 (en) * 2021-03-22 2022-09-29 Novimmune S.A. Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof
EP4314075A4 (en) * 2021-03-24 2025-04-09 Twist Bioscience Corporation VARIANT NUCLEIC ACID BANKS FOR CD3
TW202308691A (zh) * 2021-04-23 2023-03-01 瑞典商阿斯特捷利康公司 狼瘡性腎炎之治療
JP2024532159A (ja) 2021-08-20 2024-09-05 インターベット インターナショナル ベー． フェー． アトピー性皮膚炎を治療するための融合タンパク質
JP2024534643A (ja) * 2021-09-27 2024-09-20 ゾエティス・サービシーズ・エルエルシー 抗ＴＧＦβ１、２、３抗体及びその治療的使用
MX2024007089A (es) 2021-12-16 2024-08-22 Intervet Int Bv Anticuerpos caninizados para el receptor alfa i de interleucina-31 canino.
CA3258958A1 (en) 2022-02-09 2023-08-17 Zoetis Services Uk Limited Therapeutic antibodies
WO2023161526A1 (en) 2022-02-28 2023-08-31 Tridem Bioscience Gmbh & Co Kg A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN
WO2024057096A1 (en) 2022-09-14 2024-03-21 Ceva Sante Animale Treatment of atopic dermatitis using self-replicating rna expressing il-31
CN115505575B (zh) * 2022-11-16 2023-03-24 中国科学院天津工业生物技术研究所 两株分泌犬il-31单克隆抗体的杂交瘤细胞株及其应用
WO2024170486A1 (en) 2023-02-13 2024-08-22 Intervet International B.V. Canine antibodies to canine il-4
WO2024170485A1 (en) 2023-02-13 2024-08-22 Intervet International B.V. Canine antibodies to canine il-13
CN117186220A (zh) * 2023-07-20 2023-12-08 北京伟杰信生物科技有限公司 可结合白介素31的抗体或其抗原结合片段及其制备方法和应用
CN121108334A (zh) * 2024-06-11 2025-12-12 优迈生物科技(连云港)有限公司 抗犬il-31的抗体及其应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350576A (en) 1991-09-13 1994-09-27 Mycogen Corporation Bacillus thuringiensis isolates for controlling acarides
US6194167B1 (en) 1997-02-18 2001-02-27 Washington State University Research Foundation ω-3 fatty acid desaturase
AU4102099A (en) * 1998-05-29 1999-12-13 Heska Corporation Canine Interleukin -4 Proteins, Nucleic Acid Molecules, and Uses Thereof
SI1161530T1 (en) 1999-03-18 2005-10-31 Merck Patent Gmbh Protein for blocking platelet adhesion
EP1130098A3 (en) 2000-02-29 2003-09-10 Pfizer Products Inc. Mammalian osteoregulins
AU3607301A (en) * 2000-03-03 2001-09-12 Kyowa Hakko Kogyo Kk Gene recombinant antibody and its fragment
KR100419555B1 (ko) 2000-05-29 2004-02-19 주식회사유한양행 비형간염바이러스의 에스-표면항원을 인식하는단일클론항체의 가변영역 및 이를 코딩하는 유전자
US6818444B2 (en) * 2000-08-04 2004-11-16 Heska Corporation Canine and feline proteins, nucleic acid molecules and uses thereof
US20030031671A1 (en) 2001-08-01 2003-02-13 Sydney Welt Methods of treating colon cancer utilizing tumor-specific antibodies
US7261890B2 (en) 2001-12-21 2007-08-28 Idexx Laboratories, Inc. Methods for using canine immunoglobulin variable domains and caninized antibodies
CN100575482C (zh) * 2002-01-18 2009-12-30 津莫吉尼蒂克斯公司 新的细胞因子zcytor17配体
US20040208870A1 (en) 2003-01-30 2004-10-21 Medimmune, Inc. Stabilized high concentration anti-integrin alphanubeta3 antibody formulations
AU2004242847B2 (en) * 2003-05-31 2011-06-09 Amgen Research (Munich) Gmbh Pharmaceutical composition comprising a bispecific antibody for EpCAM
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
EP1671642A1 (en) 2004-12-15 2006-06-21 Universite D'angers Compositions comprising (ant)agonists of oncostatin M (OSM), IL-31 and IFN-gamma for modulating keratinocyte migration and functions via a receptor containing OSMRbeta as a subunit, and applications thereof.
WO2006081573A2 (en) 2005-01-28 2006-08-03 Zymogenetics, Inc. Homogeneous preparations of il-31
WO2008021976A2 (en) 2006-08-09 2008-02-21 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
CA2594490A1 (en) 2005-02-14 2006-08-24 Zymogenetics Inc. Methods of treating skin disorders using an il-31ra antagonist
EP1856150A2 (en) 2005-02-14 2007-11-21 ZymoGenetics, Inc. Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells
WO2006104978A2 (en) 2005-03-25 2006-10-05 Curagen Corporation Antibodies against the tenascin major antigens
US8101183B2 (en) 2005-05-06 2012-01-24 Zymogentics, Inc. Variable region sequences of IL-31 monoclonal antibodies
JP5065253B2 (ja) * 2005-05-06 2012-10-31 ザイモジェネティクス， インコーポレイテッド Ｉｌ−３１モノクローナル抗体とその使用法
EP2001906A2 (en) 2006-01-10 2008-12-17 Zymogenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using il-31ra and osmrb antagonists
CN103044550A (zh) * 2006-09-01 2013-04-17 津莫吉尼蒂克斯公司 Il-31单克隆抗体的可变区序列和使用方法
PL2829551T3 (pl) 2006-10-19 2018-04-30 Csl Limited Antagonisty przeciwciała o wysokim powinowactwie wobec receptora alfa 1 interleukiny-13
EP2215120A2 (en) 2007-12-07 2010-08-11 ZymoGenetics, Inc. Humanized antibody molecules specific for il-31
CA2733359C (en) 2008-08-20 2014-08-05 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine compounds
EP2331579B1 (en) 2008-09-04 2017-07-05 Vet Therapeutics, Inc. Monoclonal antibodies
WO2011065935A1 (en) 2009-11-24 2011-06-03 Cornell University Methods for monoclonal antibody production
WO2010117448A2 (en) * 2009-04-05 2010-10-14 Provenance Biopharmaceuticals Corp. Chimeric immunocytokines and methods of use thereof
KR20140015139A (ko) 2009-10-15 2014-02-06 애브비 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
EP2317730B1 (en) 2009-10-29 2015-08-12 Unify GmbH & Co. KG Method and system to automatically change or update the configuration or setting of a communication system
KR20230044026A (ko) 2010-02-24 2023-03-31 이뮤노젠 아이엔씨 엽산염 수용체 1 항체와 면역접합체 및 이들의 용도
KR101398290B1 (ko) * 2010-11-17 2014-05-22 추가이 세이야쿠 가부시키가이샤 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
EA201391790A1 (ru) 2011-07-22 2014-06-30 Глаксосмитклайн Байолоджикалс С.А. Очистка prame
CA3093539A1 (en) * 2018-03-16 2019-09-19 Zoetis Services Llc Interleukin-31 monoclonal antibodies for veterinary use

Also Published As

Publication number Publication date
FI3653645T3 (fi) 2024-10-25
CY1119475T1 (el) 2018-03-07
US10421807B2 (en) 2019-09-24
HRP20251544T1 (hr) 2026-01-16
ZA201400768B (en) 2015-12-23
PL3842456T3 (pl) 2025-01-20
ES2993120T3 (en) 2024-12-23
SI3842456T1 (sl) 2025-03-31
EP4679089A3 (en) 2026-04-01
BR112014001407A2 (pt) 2017-03-01
DK3842456T3 (da) 2024-10-28
HRP20241528T1 (hr) 2025-01-03
LT3219729T (lt) 2020-11-25
US9206253B2 (en) 2015-12-08
EP3219729B1 (en) 2020-09-09
US20140286958A1 (en) 2014-09-25
EP3842456A1 (en) 2021-06-30
FI3842456T3 (fi) 2024-11-12
RS66178B1 (sr) 2024-12-31
KR101613024B1 (ko) 2016-04-18
DK4459282T3 (da) 2025-12-08
DK2734549T3 (en) 2017-09-11
EP4459282A2 (en) 2024-11-06
US20260062474A1 (en) 2026-03-05
US20190389944A1 (en) 2019-12-26
PL2734549T3 (pl) 2017-11-30
CN103890009A (zh) 2014-06-25
US20190092854A1 (en) 2019-03-28
CN103890009B (zh) 2017-02-15
EP4679089A2 (en) 2026-01-14
RS56268B1 (sr) 2017-11-30
RS60924B1 (sr) 2020-11-30
US8790651B2 (en) 2014-07-29
PT3219729T (pt) 2020-10-23
EP3653645B1 (en) 2024-08-21
CA2842475A1 (en) 2013-01-24
MX2014000803A (es) 2014-03-31
US20190359702A1 (en) 2019-11-28
EP4459282A3 (en) 2025-01-08
PT4459282T (pt) 2025-12-24
ES2638340T3 (es) 2017-10-19
EP3219729A1 (en) 2017-09-20
KR101742928B1 (ko) 2017-06-01
HUE068353T2 (hu) 2024-12-28
AR087281A1 (es) 2014-03-12
AU2016203590A1 (en) 2016-06-16
LT3842456T (lt) 2024-11-11
CA2926379A1 (en) 2013-01-24
EP4459282B1 (en) 2025-10-22
MX349053B (es) 2017-07-06
PT3842456T (pt) 2024-11-29
CN105504059A (zh) 2016-04-20
LT4459282T (lt) 2025-12-29
HUE051068T2 (hu) 2021-01-28
RS66170B1 (sr) 2024-12-31
BR112014001407A8 (pt) 2022-11-08
EP3842456B1 (en) 2024-09-18
CY1123791T1 (el) 2022-03-24
HUE034282T2 (en) 2018-02-28
CN105504059B (zh) 2020-08-11
KR20160028488A (ko) 2016-03-11
MX377475B (es) 2025-03-10
RU2014101250A (ru) 2015-08-27
HRP20201634T1 (hr) 2020-12-25
DK3653645T3 (da) 2024-09-16
ME02837B (me) 2018-01-20
AU2016203590B2 (en) 2017-12-21
PT3653645T (pt) 2024-11-18
LT3653645T (lt) 2024-10-25
HRP20171198T1 (hr) 2017-10-20
RS67500B1 (sr) 2025-12-31
SI4459282T1 (sl) 2026-02-27
EP3653645A1 (en) 2020-05-20
JP2014529295A (ja) 2014-11-06
SI2734549T1 (sl) 2017-10-30
ES2827231T3 (es) 2021-05-20
US10526405B2 (en) 2020-01-07
US20130022616A1 (en) 2013-01-24
WO2013011407A1 (en) 2013-01-24
LT2734549T (lt) 2017-09-11
EP2734549A1 (en) 2014-05-28
NZ620031A (en) 2016-03-31
EP2734549B1 (en) 2017-05-24
KR20140041858A (ko) 2014-04-04
HRP20241388T1 (hr) 2024-12-20
SI3219729T1 (sl) 2020-11-30
AU2012285432C1 (en) 2016-12-22
UY34206A (es) 2013-02-28
JP6022563B2 (ja) 2016-11-09
AU2012285432B2 (en) 2016-06-16
HUE068973T2 (hu) 2025-02-28
PL3219729T3 (pl) 2021-01-25
FI4459282T3 (fi) 2025-12-18
US20140315251A1 (en) 2014-10-23
SI3653645T1 (sl) 2025-01-31
CA2842475C (en) 2018-01-02
AU2012285432A1 (en) 2014-01-30
PT2734549T (pt) 2017-08-29
ES2994801T3 (en) 2025-01-31
PL3653645T3 (pl) 2025-01-13

Similar Documents

Publication Publication Date Title
HUS2300021I1 (hu) Anti-IL-36R antitestek
PL4459282T3 (pl) Przeciwciało monoklonalne przeciwko IL-31
CO6811812A2 (es) Anticuerpo anti-b7-h3
CR20140127A (es) Anticuerpo anti-abtcr
DK2521736T3 (da) Humaniserede antistoffer
BR112014010198A2 (pt) Anticorpos humanizados que reconhecem alfa- sinucleína
PL2691417T5 (pl) Warianty fc przeciwciała
PL3415531T3 (pl) Białka wiążące antygen
PL3088421T3 (pl) Przeciwciała monoklonalne do zastosowania w diagnostyce i leczeniu nowotworów i choroby autoimmunologicznej
LT2742068T (lt) Nauji antikūnai prieš fosforilcholiną
CO6841994A2 (es) Anticuerpos
PL2581387T3 (pl) Przeciwciało monoklonalne anty-Tat HIV-1